focus -WSS

focus

author：leisure time 2025-09-27 23:33:30 - browse：75

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Judge rejects Trump's request to move Stormy Daniels hush

WSS

Ending racial health disparities hinges on penalties, political will

Paxlovid rebound happens. Why and to whom are still a mystery

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Tocagen's brain cancer gene therapy trial continues. Investors worry

Pennsylvania man bitten on the head by bear during attack in his garage

explore

focus

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

NFL doctors' conflicts of interest could endanger players, report says

Apple is now the first public company to be valued at $3 trillion

Tocagen's brain cancer gene therapy trial continues. Investors worry

Hollywood unions extend contract negotiations for actors

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Doctors push to include dialysis machines in emergency stockpile

Moonlake's readout produced a cash windfall. Risks remain

I learned firsthand about improving diversity in clinical trials

knowledge

Election results set back Medicaid expansion plans

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Judge rejects Trump's request to move Stormy Daniels hush

Paxlovid rebound happens. Why and to whom are still a mystery

Doctors are clamoring for more clarity on Paxlovid prescribing

hotspot

explore

hotspot

hotspot